search
Back to results

A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
6R-BH4 (sapropterin dihydrochloride)
Sponsored by
BioMarin Pharmaceutical
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Type 2 Diabetes, 6R-BH4, BH4, BH4 deficiency, sapropterin dihydrochloride, endothelial dysfunction, NO, Nitric Oxide

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any research-related procedures. At least 18 years of age. Willing and able to comply with all study-related procedures. History of documented essential hypertension (BP greater than or equal to 140 mm Hg systolic and/or 90 mm Hg diastolic measured on 2 separate occasions). Have poorly controlled hypertension despite use of at least two conventional antihypertensive agents with different mechanisms of action taken concurrently and consistently for at least 3 months before randomization. (Note: Antihypertensive agents may be individual or combined into a single medication.) During the two-week screening period, mean SBP and mean DBP fall within the following ranges: Mean SBP between 135 and 160 mm Hg Mean DBP between 85 and 110 mm Hg Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study. Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during this study. Individuals in the diabetic cohort must meet this additional criterion: Documented history of type 2 diabetes that has been treated using the same therapy for at least 3 months. Exclusion Criteria: Previous treatment with any formulation of BH4. Known allergy or hypersensitivity to any excipient of 6R-BH4. Known secondary cause for hypertension. Concurrent disease or condition that would interfere with study participation or safety such as bleeding disorders, history of syncope or vertigo, severe gastrointestinal reflux disease (GERD), symptomatic coronary or peripheral vascular disease, arrhythmia, organ transplant, organ failure, or type 1 diabetes mellitus. Any sever co-morbid condition that would limit life expectancy to less than 6 months. Serum creatinine >2.0mg/dL or hepatic enzyme levels more than 2 times the upper limit of normal. Requirement for concomitant treatment with any drug known to inhibit folate metabolism (e.g., methotrexate). Concomitant treatment with levodopa. Concomitant treatment with any phosphodiesterase (PDE) 5 inhibitor (e.g., Viagra(R), Cialis(R), or Levitra(R), or Revatio (TM) or any PDE 3 inhibitor (e.g., cilostazol, milrinone, or vesnarinone).) Use of any investigational product or device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments. Pregnant or breastfeeding at screening or planning to become pregnant (subject or partner) at any time during study.

Sites / Locations

Outcomes

Primary Outcome Measures

To compare oral 6R-BH4 to placebo with respect to change from baseline in arterial systolic blood pressure after 8 weeks of treatment in subjects with poorly controlled hypertension.

Secondary Outcome Measures

To compare oral 6R-BH4 to placebo with respect to change from baseline in arterial diastolic blood pressure after 8 weeks of treatment in subjects with poorly controlled hypertension
To compare oral 6R-BH4 to placebo with respect to change from baseline in insulin sensitivity after 8 weeks of treatment in subjects with both type 2 diabetes and poorly controlled hypertension
To compare oral 6R-BH4 to placebo with respect to change from baseline in eNOS activity and endothelial dysfunction after 8 weeks of treatment in subjects with poorly controlled hypertension
To assess the safety of oral dosing of 6R-BH4 in subjects with poorly controlled hypertension

Full Information

First Posted
May 11, 2006
Last Updated
July 17, 2009
Sponsor
BioMarin Pharmaceutical
search

1. Study Identification

Unique Protocol Identification Number
NCT00325962
Brief Title
A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension
Official Title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
July 2009
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
December 2006 (Actual)
Study Completion Date
December 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
BioMarin Pharmaceutical

4. Oversight

5. Study Description

Brief Summary
The purpose of this study is to determine whether 6R-BH4 (sapropterin dihydrochloride) is safe and effective in the treatment of poorly controlled hypertension in the presence or absence of type 2 diabetes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Type 2 Diabetes, 6R-BH4, BH4, BH4 deficiency, sapropterin dihydrochloride, endothelial dysfunction, NO, Nitric Oxide

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
84 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
6R-BH4 (sapropterin dihydrochloride)
Primary Outcome Measure Information:
Title
To compare oral 6R-BH4 to placebo with respect to change from baseline in arterial systolic blood pressure after 8 weeks of treatment in subjects with poorly controlled hypertension.
Secondary Outcome Measure Information:
Title
To compare oral 6R-BH4 to placebo with respect to change from baseline in arterial diastolic blood pressure after 8 weeks of treatment in subjects with poorly controlled hypertension
Title
To compare oral 6R-BH4 to placebo with respect to change from baseline in insulin sensitivity after 8 weeks of treatment in subjects with both type 2 diabetes and poorly controlled hypertension
Title
To compare oral 6R-BH4 to placebo with respect to change from baseline in eNOS activity and endothelial dysfunction after 8 weeks of treatment in subjects with poorly controlled hypertension
Title
To assess the safety of oral dosing of 6R-BH4 in subjects with poorly controlled hypertension

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to any research-related procedures. At least 18 years of age. Willing and able to comply with all study-related procedures. History of documented essential hypertension (BP greater than or equal to 140 mm Hg systolic and/or 90 mm Hg diastolic measured on 2 separate occasions). Have poorly controlled hypertension despite use of at least two conventional antihypertensive agents with different mechanisms of action taken concurrently and consistently for at least 3 months before randomization. (Note: Antihypertensive agents may be individual or combined into a single medication.) During the two-week screening period, mean SBP and mean DBP fall within the following ranges: Mean SBP between 135 and 160 mm Hg Mean DBP between 85 and 110 mm Hg Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study. Females of childbearing potential must have a negative pregnancy test at screening and be willing to have additional pregnancy tests during this study. Individuals in the diabetic cohort must meet this additional criterion: Documented history of type 2 diabetes that has been treated using the same therapy for at least 3 months. Exclusion Criteria: Previous treatment with any formulation of BH4. Known allergy or hypersensitivity to any excipient of 6R-BH4. Known secondary cause for hypertension. Concurrent disease or condition that would interfere with study participation or safety such as bleeding disorders, history of syncope or vertigo, severe gastrointestinal reflux disease (GERD), symptomatic coronary or peripheral vascular disease, arrhythmia, organ transplant, organ failure, or type 1 diabetes mellitus. Any sever co-morbid condition that would limit life expectancy to less than 6 months. Serum creatinine >2.0mg/dL or hepatic enzyme levels more than 2 times the upper limit of normal. Requirement for concomitant treatment with any drug known to inhibit folate metabolism (e.g., methotrexate). Concomitant treatment with levodopa. Concomitant treatment with any phosphodiesterase (PDE) 5 inhibitor (e.g., Viagra(R), Cialis(R), or Levitra(R), or Revatio (TM) or any PDE 3 inhibitor (e.g., cilostazol, milrinone, or vesnarinone).) Use of any investigational product or device within 30 days prior to screening, or requirement for any investigational agent prior to completion of all scheduled study assessments. Pregnant or breastfeeding at screening or planning to become pregnant (subject or partner) at any time during study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Martha Nicholson, MD
Organizational Affiliation
BioMarin Pharmaceutical
Official's Role
Study Director
Facility Information:
City
Hoover
State/Province
Alabama
Country
United States
City
Huntsville
State/Province
Alabama
Country
United States
City
Mobile
State/Province
Alabama
Country
United States
City
Muscle Shoals
State/Province
Alabama
Country
United States
City
Gilbert
State/Province
Arizona
Country
United States
City
Phoenix
State/Province
Arizona
Country
United States
City
Anaheim
State/Province
California
Country
United States
City
Burbank
State/Province
California
Country
United States
City
Cudahy
State/Province
California
Country
United States
City
Long Beach
State/Province
California
Country
United States
City
Roseville
State/Province
California
Country
United States
City
San Francisco
State/Province
California
Country
United States
City
Denver
State/Province
Colorado
Country
United States
City
Pembroke Pines
State/Province
Florida
Country
United States
City
Atlanta
State/Province
Georgia
Country
United States
City
Decatur
State/Province
Georgia
Country
United States
City
Indianapolis
State/Province
Indiana
Country
United States
City
Auburn
State/Province
Maine
Country
United States
City
Scarborough
State/Province
Maine
Country
United States
City
Baltimore
State/Province
Maryland
Country
United States
City
Charlotte
State/Province
North Carolina
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Knoxville
State/Province
Tennessee
Country
United States
City
Carrollton
State/Province
Texas
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.bmrn.com
Description
BioMarin Pharmaceutical Inc. website

Learn more about this trial

A Study of the Effects of 6R-BH4 on Blood Pressure in Subjects With Poorly Controlled Systemic Hypertension

We'll reach out to this number within 24 hrs